Summary: “With the prospect of FDA approval, which experts say could happen as early as 2023, combined with MAPS’ position of leading the MDMA-assisted therapy market, the organization will surely lead lobbying efforts to induce healthcare insurance companies to cover such treatments,” explains David Carpenter in Benzinga.